Erythropoietin

Last updated: February 23, 2023

Erythropoietin

Julie-Anne's playlist

Julie-Anne's playlist

Vitamin D
Parathyroid hormone
Phosphate, calcium and magnesium homeostasis
Parathyroid disorders and calcium imbalance: Pathology review
Parathyroid conditions and calcium imbalance: Clinical
Thyroid and parathyroid gland histology
TF/Px ratio and TF/Pinulin
Measuring renal plasma flow and renal blood flow
Regulation of renal blood flow
Tubular reabsorption and secretion
Tubular secretion of PAH
Tubular reabsorption of glucose
Urea recycling
Tubular reabsorption and secretion of weak acids and bases
Proximal convoluted tubule
Loop of Henle
Distal convoluted tubule
Renin-angiotensin-aldosterone system
Sodium homeostasis
Potassium homeostasis
Osmoregulation
Antidiuretic hormone
Kidney countercurrent multiplication
Free water clearance
Erythropoietin
Physiologic pH and buffers
Buffering and Henderson-Hasselbalch equation
The role of the kidney in acid-base balance
Acid-base map and compensatory mechanisms
Respiratory acidosis
Metabolic acidosis
Plasma anion gap
Respiratory alkalosis
Metabolic alkalosis
Hypernatremia: Clinical
Hyponatremia: Clinical
Hyperkalemia: Clinical
Hypokalemia: Clinical
Metabolic and respiratory alkalosis: Clinical
Toxidromes: Clinical
Acute kidney injury: Clinical
Chronic kidney disease: Clinical
Urinary tract infections: Clinical
Nephritic and nephrotic syndromes: Clinical
Renal tubular defects: Pathology review
Renal tubular acidosis: Pathology review
Osmotic diuretics
Carbonic anhydrase inhibitors
Loop diuretics
Thiazide and thiazide-like diuretics
Potassium sparing diuretics
Diffuse parenchymal lung disease: Clinical
Restrictive lung diseases: Pathology review
Chronic obstructive pulmonary disease (COPD): Clinical
Chronic bronchitis
Obstructive lung diseases: Pathology review
Emphysema
Pulmonary hypertension
Cor pulmonale
Sympathomimetics: Direct agonists
Muscarinic antagonists
Psychomotor stimulants
Mycobacterium avium complex (NORD)
Asthma: Clinical
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines
Pneumonia: Clinical
Metabolic and respiratory acidosis: Clinical
Rhinovirus

Transcript

Watch video only

With erythropoietin, ‘-poietin’ means ‘to make’ and ‘erythro-’ refers to red blood cells, so erythropoietin is a hormone that stimulates the production of erythrocytes or red blood cells in the bone marrow. Erythropoietin, or EPO, is produced in the kidneys, and to a lesser extent in the liver, and travels through the blood to the bone marrow where it stimulates immature cells to transform into mature red blood cells.

Every cell in the body uses oxygen for cellular respiration. As we breathe, oxygen diffuses into the bloodstream where it binds hemoglobin within the red blood cells and gets carried off to various parts of the body. Red blood cells live for about 120 days, so there is a constant need to produce new red blood cells.

Now, in the bone marrow, there are proerythroblasts, which are primitive or immature red blood cells. The kidneys produce a constant level of erythropoietin, which gets released into the blood and makes its way to the bone marrow, where it binds to erythropoietin receptors on the immature red blood cells and causes them to erythrocytes, or mature into red blood cells, usually this production of erythropoietin is constant, so the production of mature red blood cells is constant. If there’s ever decreased oxygen delivery to the tissues, then one thing the body can do is ramp up production of oxygen delivery vehicles, in other words red blood cells. In this situation, the kidney cells ramp up production of erythropoietin, therefore ramping up production of mature red blood cells. Interestingly, erythropoietin prevents immature red blood cells from killing themselves by apoptosis, meaning that without erythropoietin, developing red blood cells die via apoptosis.

Fundamentally, decreased oxygen delivery to the tissues can be due to a decrease in blood flow or a decrease in blood oxygen content. If there’s a decrease in blood flow, then increasing the number of red blood cells is not effective, however, if there’s a decreased oxygen content, then increasing the number of red blood cells is effective and will help with oxygen delivery. 

Key Takeaways

Erythropoietin (EPO) is a hormone that regulates the production of red blood cells. EPO is produced by kidney cells, and can be deficient in individuals with chronic kidney diseases, resulting in reduced production of red blood cells, thus anemia.

EPO is made in response to low oxygen levels in the tissues. It signals the bone marrow to produce more red blood cells, which helps to increase oxygen delivery to tissues. EPO is also used as a doping agent in endurance sports because it can improve performance by increasing the amount of oxygen that is delivered to muscles. EPO doping has been reported to have negative health effects, including an increased risk of heart attack and stroke.

Sources

  1. "Medical Physiology" Elsevier (2016)
  2. "Physiology" Elsevier (2017)
  3. "Human Anatomy & Physiology" Pearson (2018)
  4. "Principles of Anatomy and Physiology" Wiley (2014)
  5. "Erythropoietin" BMJ (1964)
  6. "Erythropoietin" BMJ (1964)